Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. May 15, 2021; 13(5): 351-365
Published online May 15, 2021. doi: 10.4251/wjgo.v13.i5.351
Published online May 15, 2021. doi: 10.4251/wjgo.v13.i5.351
Figure 1 Multiple molecular biomarkers derived from blood, urine, and feces, including proteins, metabolites, circulating nucleic acids, circulating tumor cells, extracellular vesicles, and gut microbiota, have great potential to diagnose early hepatocellular carcinoma, predict responses to specific therapies, evaluate prognoses before or after therapies, and be developed as new therapeutic targets for this tumor.
P: Proteins; M: Metabolites.
- Citation: Guan MC, Ouyang W, Wang MD, Liang L, Li N, Fu TT, Shen F, Lau WY, Xu QR, Huang DS, Zhu H, Yang T. Biomarkers for hepatocellular carcinoma based on body fluids and feces. World J Gastrointest Oncol 2021; 13(5): 351-365
- URL: https://www.wjgnet.com/1948-5204/full/v13/i5/351.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i5.351